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data from a community-wide screening and
treatment of asymptomatic carriers in Burkina
Faso
Alfred B Tiono1*, Sodiomon B Sirima1 and Kamal Hamed2Abstract
Background: The Fulani ethnic group is known to have a lower susceptibility to Plasmodium falciparum infection
than the Mossi.
Methods: This commentary describes data from a recent cluster-randomized trial of community-wide screening
and treatment of asymptomatic carriers of P. falciparum in 18 villages in Saponé, Burkina Faso.
Results: The Fulani groups had a lower proportion of asymptomatic carriers at any occasion, a lower density of
asexual forms and gametocytes of P. falciparum at baseline, and, in children under five years of age, lower rates of
symptomatic malaria episodes per person-year than the Mossi.
Discussion and conclusion: These data confirm previously reported differences in P. falciparum susceptibility
between Fulani and Mossi.
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Recent investigations into the ethnic susceptibility of Fu-
lani and Mossi for Plasmodium falciparium infection
have consistently reported that Fulani have a lower
susceptibility than Mossi [1-5]. A recent cluster-
randomized trial in 18 villages in Saponé, Burkina Faso,
which investigated the systematic, community-wide
screening and treatment of asymptomatic carriers of
P. falciparum with artemether-lumefantrine (AL) [6],
provided further data on the susceptibility differences
between these two ethnic groups. This trial enrolled a
combined majority of Fulani and Mossi subjects and
assessed the incidence of microscopy-confirmed asymp-
tomatic carriage, asexual forms and gametocytes, as well
as ‘symptomatic malaria episodes including fever and a* Correspondence: t.alfred@fasonet.bf
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reproduction in any medium, provided the orparasite density >5,000/μl’ (abbreviated as SMRC5000
throughout the text) at various time points over the 12-
month study [6].
While the exact biological reason for the lower suscep-
tibility to P. falciparum of Fulani compared with Mossi
is not fully understood, it is known that it is not due to
an increased frequency of classic malaria-resistance
genes, such as haemoglobin S, haemoglobin C, -alpha
3.7 deletional thalassaemia, G6PDA-, and HLA B*5301
[7]. However, Fulani have been shown to have higher
levels of antibodies against two P. falciparum antigens
[3] and stronger malaria-specific IgG, IgG1, IgG3 and
IgM responses [8].
Further investigations into immunological differences
that may affect susceptibility to P. falciparum have
centred on FcγRIIa genotypes that affect the binding of
different IgG subclasses. The FcγRIIa-H/H131 genotype
is associated with higher levels of anti-malarial IgG2 and
IgG3 antibodies, while the FcγRIIa-R/R131 genotype istd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 P. falciparum microscopy-confirmed asymptomatic
carriers at any occasion.
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Individuals with the R allele of FcγRIIa have higher anti-
body levels than those with the H allele [11]. The
FcγRIIa-H/H131 genotype and H131 allele are reported
to exist at higher frequencies in the Fulani ethnic group
[10]. However, there is a similar distribution of FcγRIIa-
R131H polymorphism in Fulani and Mossi [11]. Overall,
Fulani have higher antibody levels than Mossi [11]. Add-
itionally, in Fulani, it is known that the IL4-524 T allele,
which codes for the Th2 cytokine interleukin-4, is at
high frequency and is associated with elevated antibody
levels against malarial antigens [12]. A functional deficit
of T regulatory cells may also contribute to Fulani
having a higher resistance to malaria [4].
It has also been demonstrated that parasitaemia
in asymptomatic Fulani is more common in individuals with
lactase non-persistence genotypes (lactose intolerance), al-
though this difference was not statistically significant [5].
This suggests that the potential immunoprotective proper-
ties of dietary cow’s milk may contribute to the partial
malaria resistance of Fulani, yet this requires further in-
vestigation [5].
This commentary describes differences in susceptibil-
ity to P. falciparum infection between Fulani and Mossi
subjects in the above-mentioned study [6].Ethics section
The protocol and the informed consent form were
reviewed and approved by the Institutional Review
Board of the Centre National de Recherche et de Forma-
tion sur le Paludisme and by the National Ethical Com-
mittee for Health Research of Burkina Faso. Prior to
study initiation, a community meeting was held in each
of the selected clusters to discuss the study with the
community. The freedom of each individual household
and a household member to decide on participation was
discussed to minimize the potential influence of key
opinion leaders in each cluster. Individual informed con-
sent was obtained from each participant during a visit to
the household before any study procedure.Figure 2 Density of P. falciparum asexual forms by microscopy
at baseline.Results
Baseline characteristics
In total, 14,075 subjects aged between one month and
104 years were enrolled. The intervention arm in-
cluded 6,817 subjects with a mean age of 24.1 years,
of whom 46.4% were male, 90.6% were Mossi and
8.7% were Fulani. The control arm included 7,258
subjects with a mean age of 23.4 years, of whom
47.4% were male, 95.7% were Mossi and 3.8% were
Fulani. The intervention and control arms had similar
proportions of children less than five years of age
(17.0% and 15.6%, respectively).Plasmodium falciparum infection rates by ethnicity
Proportions of asymptomatic carriers
The Fulani groups had a lower proportion of microscopy-
confirmed asymptomatic carriers than the Mossi groups
at any occasion (Figure 1). Subjects may have been
counted multiple times if diagnosed as asymptomatic car-
riers more than once during the study.
Parasite densities (asexual forms and gametocytes)
The Fulani groups had lower densities of microscopy-
confirmed P. falciparum asexual forms (Figure 2) and
gametocytes (Figure 3) than the Mossi groups at
baseline.
Incidence of SMRC5000
In children under five years of age, the Fulani groups
had lower rates of SMRC5000 per person-year than the
Mossi groups at follow-up (Table 1). However, when the
analysis included subjects of all ages, the Fulani groups
Table 2 SMRC5000* per person-year in subjects of all
ages at follow-up (all subjects diagnosed at any time
with asymptomatic carriage)








Mossi 722 1928.1 0.37
Fulani 57 116.8 0.49
Control
(n = 1,381)
Mossi 257 1024.2 0.25
Fulani 14 29.2 0.48
* SMRC5000 = Symptomatic malaria episodes including fever and a parasite
density >5,000/μl.
Figure 3 Density of P. falciparum gametocytes by microscopy
at baseline.
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Mossi groups (Table 2).Discussion
Demographic surveillance data for the district show the
distribution of Fulani and Mossi in the area as 7.1% and
90.7%, respectively. The proportions of each group en-
rolled in the study are generally consistent with this
(8.7% and 90.6% in the intervention arm, 3.8% and
95.7% in the control arm).
The data we present confirm previously reported dif-
ferences in susceptibility to P. falciparum malaria
between Fulani and Mossi ethnic groups [1-5]. There
was a consistently reduced incidence of the indicators
for P. falciparum infection in Fulani over Mossi
(Figures 1, 2 and 3 and Table 1), except for a reversal of
this trend in the rates of SMRC5000 per person-year in
subjects of all ages at follow-up (all subjects diagnosed
at any time for asymptomatic carriage, Table 2).Table 1 SMRC5000* per person-year in infants and
children (under five years) at follow-up (all subjects
diagnosed at any time with asymptomatic carriage)








Mossi 384 350.6 1.10
Fulani 31 32.8 0.95
Control
(n = 203)
Mossi 154 149.1 1.03
Fulani 7 9.3 0.76
* SMRC5000 = Symptomatic malaria episodes including fever and a parasite
density >5,000/μl.This inconsistency in SMRC5000 per person-year in
infants and children (under five years) and in subjects
of all ages at follow-up (Tables 1 and 2) was unantici-
pated. One possible reason for this may be that treat-
ment of asymptomatic carriers with artemisinin-based
therapy may increase subsequent susceptibility to
symptomatic malaria more in adult Fulani who are
known to have stronger immune responses to malaria
than in Mossi.
Therefore, areas for further research include a more
detailed assessment of differences in SMRC5000 (per
person-year) between children and adults and any bio-
logical reasons for these differences, as well as investiga-
tions into potential interethnic differences in the effect
of artemisinin derivatives on naturally acquired protect-
ive immunity. Other beneficial studies may assess intra-
Fulani susceptibility distribution, which may correlate
with previously reported differences in anti-malarial
antibody levels amongst the Fulani themselves [12].
Conclusion
Data from the systematic, community-wide screening
and treatment of asymptomatic carriers of P. falciparum
with artemether-lumefantrine (AL) [6] confirm previ-
ously reported differences in P. falciparum susceptibility
between Fulani and Mossi.
Abbreviations
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